Seminars in Oncology
Volume 34, Issue 6 , Pages 491-497 , December 2007

Reflecting on the 2001 American Joint Committee on Cancer Staging System for Melanoma

  • Spyros Retsas

      Affiliations

    • Oncology Centre, Cromwell Hospital, London, UK.
    • Corresponding Author InformationAddress correspondence to Spyros Retsas, MD, FRCP, Consultant Medical Oncologist, Oncology Centre, Cromwell Hospital, Cromwell Road, London SW5 0TU, UK.
    • ,
  • Michael J. Mastrangelo

      Affiliations

    • Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.

References 

  1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  2. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  3. Retsas S, Henry K, Mohammed MQ, et al. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): Validation in a cohort of 1284 patients. Eur J Cancer. 2002;38:511–516
  4. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488–1498
  5. Berd D, Mastrangelo MJ, Sato T. Calculation of survival of patients with stage III melanoma. J Clin Oncol. 2005;23:9427
  6. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–908
  7. Leiter U, Buettner PG, Eigentler TK, et al. Prognostic factors of thin cutaneous melanoma: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. J Clin Oncol. 2004;22:3660–3667
  8. McKinnon JG, Yu XQ, McCarthy WH, et al. Prognosis for patients with thin cutaneous melanoma: Long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223–1231
  9. Michels JJ, Marnay J, Delozier T, et al. Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer. 2004;100:455–464
  10. McGovern VJ, Shaw HM, Milton GW, et al. Prognostic significance of the histological features of malignant melanoma. Histopathology. 1979;3:385–393
  11. Karjalainen JM, Eskelinen MJ, Nordling S, et al. Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma. Br J Cancer. 1998;77:1917–1925
  12. Sondergaard K, Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases (A multivariate regression analysis). Virchows Arch A Pathol Anat Histopathol. 1985;406:179–195
  13. Ostmeier H, Fuchs B, Otto F, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?. Cancer. 1999;85:2391–2399
  14. Shaw HM, McCarthy WH, McCarthy SW, et al. Thin malignant melanomas and recurrence potential. Arch Surg. 1987;122:1147–1150
  15. Smolle J, Hofmann-Wellenhof R, Kofler R, et al. Tumor cell proliferation and motility estimates are prognostic factors in malignant melanoma. Anal Cell Pathol. 1993;5:113–124
  16. Massi D, Borgognoni L, Franchi A, et al. Thick cutaneous malignant melanoma: A reappraisal of prognostic factors. Melanoma Res. 2000;10:153–164
  17. Retsas S. On the antiquity of cancer from Hippocrates to Galen. In:  Retsas S editors. Palaeo-Oncology: The Antiquity of Cancer. London, UK: Farrand Press; 1986;p. 41–58
  18. Karjalainen JM, Kellokoski JK, Eskelinen MJ, et al. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol. 1998;16:3584–3591
  19. O’Brien CJ, Coates AS, Petersen-Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991;162:310–314
  20. Retsas S, Quigley M, Pectasides D, et al. Clinical and histologic involvement of regional lymph nodes in malignant melanoma (Adjuvant vindesine improves survival). Cancer. 1994;73:2119–2130
  21. Cochran AJ, Elashoff D, Morton DL, et al. Individualized prognosis for melanoma patients. Hum Pathol. 2000;31:327–331
  22. Guerry D, Botbyl J, Gimotty A. A population based validation of the AJCC melanoma staging system. J Clin Oncol. 2004;22:710s;(abstr 7500)
  23. Schmid-Wendtner MH, Baumert J, Schmidt M, et al. Prognostic index for cutaneous melanoma: An analysis after follow-up of 2715 patients. Melanoma Res. 2001;11:619–626
  24. Kopf AW, Gross DF, Rogers GS, et al. Prognostic index for malignant melanoma. Cancer. 1987;59:1236–1241
  25. Gimotty PA, Van BP, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048–8056
  26. Busam KJ. The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma. Ann Surg Oncol. 2004;11:360–361
  27. Balch CM, Soong S-J, Desmond R. In reply. J Clin Oncol. 2005;23:9428
  28. Rangel J, Torabian S, Shaikh L, et al. NCOA3: A molecular prognostic marker for melanoma. J Clin Oncol. 2006;24:454s;(abstr 8007)
  29. Donato R. Perspectives in S-100 protein biology (Review article). Cell Calcium. 1991;12:713–726
  30. Cochran AJ, Wen DR. S-100 protein as a marker for melanocytic and other tumours. Pathology. 1985;17:340–345
  31. Nakajima T, Watanabe S, Sato Y, et al. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer. 1982;50:912–918
  32. Retsas S, Falkson C. 2nd International Conference on the Adjuvant Therapy of Malignant Melanoma (London, UK, 14-15 March, 1997. Report and abstracts). Melanoma Res. 1997;7:153–173
  33. Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:924–928
  34. Abraha HD, Fuller LC, Du Vivier AW, et al. Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol. 1997;137:381–385
  35. Schultz ES, Diepgen TL, Von Den DP. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol. 1998;38:426–430
  36. Henze G, Dummer R, Joller-Jemelka HI, et al. Serum S100—A marker for disease monitoring in metastatic melanoma. Dermatology. 1997;194:208–212
  37. Martenson ED, Hansson LO, Nilsson B, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824–831
  38. Hauschild A, Michaelsen J, Brenner W, et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res. 1991;9:155–161
  39. Mohammed MQ, Abraha HD, Sherwood RA, et al. Serum S100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol. 2001;18:109–120
  40. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  41. Spitler LE. Adjuvant therapy of melanoma. Oncology (Williston Park). 2002;16(suppl 1):40–48
  42. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18 F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178–1187

PII: S0093-7754(07)00181-9

doi: 10.1053/j.seminoncol.2007.09.005

Seminars in Oncology
Volume 34, Issue 6 , Pages 491-497 , December 2007

Article Tools

* Image Usage & Resolution